Dexcom (DXCM) Other Accumulated Expenses (2011 - 2026)

Dexcom (DXCM) has 16 years of Other Accumulated Expenses data on file, last reported at $7.6 million in Q1 2026.

• On a quarterly basis, Other Accumulated Expenses fell 84.89% year-over-year to $7.6 million in Q1 2026; TTM through Mar 2026 was $7.6 million, a 84.89% decrease from a year earlier, with the FY2025 full-year figure at $7.7 million, down 79.25% from the prior year.
• Other Accumulated Expenses for Q1 2026 stood at $7.6 million, down from $7.7 million in the prior quarter.
• Over the last five years, Other Accumulated Expenses for DXCM reached as high as $62.9 million in Q1 2022 and fell as low as $7.6 million in Q1 2026.
• Historically, Other Accumulated Expenses has averaged $40.5 million across 5 years, with a median of $42.0 million in 2025.
• Across the five-year window, Other Accumulated Expenses surged 41.67% in 2022 and tumbled 84.89% in 2026, its largest moves.
• Year by year, Other Accumulated Expenses stood at $39.7 million in 2022, then gained by 2.02% to $40.5 million in 2023, then retreated by 8.4% to $37.1 million in 2024, then sank by 79.25% to $7.7 million in 2025, then retreated by 1.3% to $7.6 million in 2026.
• Per Business Quant data, the three most recent Other Accumulated Expenses figures were $7.6 million in Q1 2026, $7.7 million in Q4 2025, and $42.0 million in Q3 2025.